A Phase I Study of Gemcitabine, Carboplatin and Lenalidomide (GCL) for Treatment of Patients With Advanced/Metastatic Urothelial Carcinoma (UC) and Other Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2017
At a glance
- Drugs Lenalidomide (Primary) ; Carboplatin; Gemcitabine
- Indications Solid tumours; Urogenital cancer
- Focus Adverse reactions
- 07 Aug 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
- 06 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 06 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.